Crinetics Pharmaceuticals Common Stock Net 2017-2024 | CRNX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Crinetics Pharmaceuticals common stock net from 2017 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Crinetics Pharmaceuticals common stock net from 2017 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$88.7B
Takeda Pharmaceutical (TAK)	$47.3B
Merck (MKGAF)	$23.7B
Astellas Pharma (ALPMY)	$21.5B
Summit Therapeutics (SMMT)	$19B
Sandoz Group AG (SDZNY)	$17.5B
United Therapeutics (UTHR)	$15.4B
Shionogi (SGIOY)	$13.3B
Neurocrine Biosciences (NBIX)	$12.4B
Catalent (CTLT)	$11B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.3B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.1B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.1B
Corcept Therapeutics (CORT)	$4.1B
Dyne Therapeutics (DYN)	$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
PTC Therapeutics (PTCT)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.5B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
Xencor (XNCR)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.5B
Cassava Sciences (SAVA)	$1.5B
Ardelyx (ARDX)	$1.4B